Investigations into the effects of novel lipid-lowering therapies, such as Proprotein convertase subtilisin/kexin type 9(PCSK9) inhibitors, on AIP-associated functional decline are also warranted. Here, PCSK9 is linked to autoimmune pancreatitis.